Bajaj Healthcare specializes in manufacturing intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.
The company reported a standalone net loss of Rs 22.85 crore in Q4 FY26, compared with a net profit of Rs 11.17 crore posted in Q4 FY25. Revenue from operations shed 0.91% YoY to Rs 153.05 crore in Q4 FY26, compared with Rs 154.47 crore in the corresponding quarter last year.
The counter declined 1.91% to settle at Rs 305.50 on the BSE.
Powered by Capital Market - Live News